Cargando…

Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome

BACKGROUND: Intensive statin therapy decreases mortality and incidence of coronary events in patients after acute coronary syndrome (ACS). Recently it has been reported that spontaneous lipid levels remain clinically stable during ACS. The immediate influence of lipid levels by high-dose statin ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vondrakova, Dagmar, Ostadal, Petr, Kruger, Andreas
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914010/ https://www.ncbi.nlm.nih.gov/pubmed/20630099 http://dx.doi.org/10.1186/1476-511X-9-71

Ejemplares similares

Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers
por: Ostadal, Petr, et al.
Publicado: (2012)

Continual measurement of arterial dP/dt(max) enables minimally invasive monitoring of left ventricular contractility in patients with acute heart failure
por: Ostadal, Petr, et al.
Publicado: (2019)

Blood levels of copeptin on admission predict outcomes in out-of-hospital cardiac arrest survivors treated with therapeutic hypothermia
por: Ostadal, Petr, et al.
Publicado: (2012)

Association of neuron-specific enolase values with outcomes in cardiac arrest survivors is dependent on the time of sample collection
por: Vondrakova, Dagmar, et al.
Publicado: (2017)

Acute Severe Heart Failure Reduces Heart Rate Variability: An Experimental Study in a Porcine Model
por: Naar, Jan, et al.
Publicado: (2022)

Cardiac Arrest as an Uncommon Manifestation of Late Type A Aortic Dissection Associated with Transcatheter Aortic Valve Replacement
por: Naar, Jan, et al.
Publicado: (2023)

Electrocardiogram-synchronized pulsatile extracorporeal life support preserves left ventricular function and coronary flow in a porcine model of cardiogenic shock
por: Ostadal, Petr, et al.
Publicado: (2018)

A Total of 207 Days of Veno-Venous Extracorporeal Membrane Oxygenation Support for Severe COVID-19 Prior to Successful Lung Transplantation: A Case Report
por: Naar, Jan, et al.
Publicado: (2022)

Aortic stenosis and mitral regurgitation modify the effect of venoarterial extracorporeal membrane oxygenation on left ventricular function in cardiogenic shock
por: Ostadal, Petr, et al.
Publicado: (2022)

Effect of atorvastatin therapy on borderline vulnerable lesions in patients with acute coronary syndrome
por: Yu, Dan-Qing, et al.
Publicado: (2011)

Atorvastatin inhibits the immediate-early response gene EGR1 and improves the functional pro of CD4(+)T-lymphocytes in acute coronary syndromes
por: Severino, Anna, et al.
Publicado: (2017)

Increasing venoarterial extracorporeal membrane oxygenation flow negatively affects left ventricular performance in a porcine model of cardiogenic shock
por: Ostadal, Petr, et al.
Publicado: (2015)

Long-term benefits of high-intensity atorvastatin therapy in Chinese acute coronary syndrome patients undergoing percutaneous coronary intervention: A retrospective study
por: Liu, Hui, et al.
Publicado: (2018)

Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome
por: Liu, Zhi, et al.
Publicado: (2017)

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Markers in Acute Coronary Syndrome
por: Umrani, Salman, et al.
Publicado: (2020)

Effect of Atorvastatin on Serial Changes in Coronary Physiology and Plaque Parameters
por: Lee, Cheol Hyun, et al.
Publicado: (2022)

Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction – A report from FAR NHL prospective registry
por: Spinar, Jindrich, et al.
Publicado: (2019)

Comparative Effectiveness of Generic Atorvastatin and Lipitor(®) in Patients Hospitalized with an Acute Coronary Syndrome
por: Jackevicius, Cynthia A., et al.
Publicado: (2016)

Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
por: Khurana, Sushant, et al.
Publicado: (2015)

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients with Acute Coronary Syndrome
por: Kumar, Besham, et al.
Publicado: (2019)

Changes in Homocysteine Levels Affect Serum Lipid Response to Atorvastatin in Patients With Acute Coronary Syndrome: A Retrospective Observational Study
por: Wu, Dong-Feng, et al.
Publicado: (2020)

Sex-Specific Influence of the SCARB1 Rs5888 SNP on the Serum Lipid Response to Atorvastatin in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Wu, Dong-Feng, et al.
Publicado: (2020)

The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational study
por: Ma, Huan, et al.
Publicado: (2017)

Efficacy and safety of Zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease
por: Xu, Danyan, et al.
Publicado: (2017)

Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse
por: Ai, Cong, et al.
Publicado: (2018)

The effects of atorvastatin therapy on endothelıal function in patients with coronary artery disease
por: Yildiz, Ahmet, et al.
Publicado: (2007)

Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease
por: Zhao, Yuhong, et al.
Publicado: (2017)

Effect of loading dose of atorvastatin therapy prior to percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of six randomized controlled trials
por: Ma, Mingfeng, et al.
Publicado: (2019)

Vitamin D Levels and Lipid Response to Atorvastatin
por: Pérez-Castrillón, José Luis, et al.
Publicado: (2010)

Management of hyperglycemia during and in the immediate follow-up of acute coronary syndrome
por: El Ouazzani, Jamal, et al.
Publicado: (2018)

An intensive, structured, mobile devices-based healthcare intervention to optimize the lipid-lowering therapy improves lipid control after an acute coronary syndrome
por: Ruiz-Bustillo, Sonia, et al.
Publicado: (2022)

Extracorporeal membrane oxygenation (ECMO) in the management of non-surgical patients with cardiogenic shock and cardiac arrest
por: Ostadal, P, et al.
Publicado: (2015)

Effects of high versus low-dose atorvastatin on high sensitive C-reactive protein in acute coronary syndrome
por: Zamani, Bijan, et al.
Publicado: (2014)

Does Pre-Treatment with High Dose Atorvastatin Prevent Microvascular Dysfunction after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome?
por: Lee, Bong-Ki, et al.
Publicado: (2016)

Comparison of the effect of 40 and 80 mg/day doses of atorvastatin on changes in lipid profiles among acute coronary syndrome patients: A randomized clinical trial study
por: Sahebkar, Mohammad, et al.
Publicado: (2023)

Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)
por: Ostadal, Petr, et al.
Publicado: (2010)

Effect of CETP Polymorphism on Atorvastatin Lipid-Regulating Effect and Clinical Prognosis of Patients with Coronary Heart Disease
por: Gu, Guo-Long, et al.
Publicado: (2014)

Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]
por: Ostadal, Petr, et al.
Publicado: (2005)

Atorvastatin-induced acute pancreatitis
por: Deshpande, Prasanna R., et al.
Publicado: (2011)

Smoking cessation after an acute coronary syndrome: immediate quitters are successful quitters
por: Snaterse, M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lmvorta7n5a1h09jvb3n5qsljk